Hyun-U Cho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hyun-U Cho has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Dong Pyo Jang
Department of Biomedical Engineering, Hanyang University, Seoul, Republic of Korea
2 shared publications - Changjoon Justin Lee
Center for Memory and Glioscience, Institute for Basic Science, Daejeon, Republic of Korea
1 shared publication - Chul-Ho Lee
Department of Electrical and Computer Engineering, Seoul National University, Seoul, Republic of Korea
1 shared publication Gwan‐Jin Ko
KU‐KIST Graduate School of Converging Science and Technology Korea University 145 Anam‐ro, Seongbuk‐gu Seoul 02841 Republic of Korea
1 shared publicationHeeyoung An
KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, Korea
1 shared publicationHuanyu Cheng
Department of Engineering Science and Mechanics The Pennsylvania State University University Park Pennsylvania 16802 USA
1 shared publication
Latest Publications
- 24 January 2022
- Published by Wiley in Advanced Materials
- Vol. 34 (14) , 2108203
Hetero‐Integration of Silicon Nanomembranes with 2D Materials for Bioresorbable, Wireless Neurochemical System
Although neurotransmitters are key substances closely related to evaluating degenerative brain diseases as well as regulating essential functions in the body, many research efforts have not been focused on direct observation of such biochemical messengers, rather on monitoring relatively associated physical, mechanical, and electrophysiological parameters. Here, a bioresorbable silicon‐based neurochemical analyzer incorporated with 2D transition metal dichalcogenides is introduced as a completely implantable brain‐integrated system that can wirelessly monitor time‐dynamic behaviors of dopamine and relevant parameters in a simultaneous mode. An extensive range of examinations of molybdenum/tungsten disulfide (MoS2/WS2) nanosheets and catalytic iron nanoparticles (Fe NPs) highlights the underlying mechanisms of strong chemical and target‐specific responses to the neurotransmitters, along with theoretical modeling tools. Systematic characterizations demonstrate reversible, stable, and long‐term operational performances of the degradable bioelectronics with excellent sensitivity and selectivity over those of non‐dissolvable counterparts. A complete set of in vivo experiments with comparative analysis using carbon‐fiber electrodes illustrates the capability for potential use as a clinically accessible tool to associated neurodegenerative diseases.
- 24 January 2022
- Published by Wiley in Advanced Materials
- Vol. 34 (14) , 2108203
Hetero‐Integration of Silicon Nanomembranes with 2D Materials for Bioresorbable, Wireless Neurochemical System
Although neurotransmitters are key substances closely related to evaluating degenerative brain diseases as well as regulating essential functions in the body, many research efforts have not been focused on direct observation of such biochemical messengers, rather on monitoring relatively associated physical, mechanical, and electrophysiological parameters. Here, a bioresorbable silicon‐based neurochemical analyzer incorporated with 2D transition metal dichalcogenides is introduced as a completely implantable brain‐integrated system that can wirelessly monitor time‐dynamic behaviors of dopamine and relevant parameters in a simultaneous mode. An extensive range of examinations of molybdenum/tungsten disulfide (MoS2/WS2) nanosheets and catalytic iron nanoparticles (Fe NPs) highlights the underlying mechanisms of strong chemical and target‐specific responses to the neurotransmitters, along with theoretical modeling tools. Systematic characterizations demonstrate reversible, stable, and long‐term operational performances of the degradable bioelectronics with excellent sensitivity and selectivity over those of non‐dissolvable counterparts. A complete set of in vivo experiments with comparative analysis using carbon‐fiber electrodes illustrates the capability for potential use as a clinically accessible tool to associated neurodegenerative diseases.
- Open Access
- 9 July 2021
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 53 (7) , 1148-1158
Redefining differential roles of MAO-A in dopamine degradation and MAO-B in tonic GABA synthesis
Monoamine oxidase (MAO) is believed to mediate the degradation of monoamine neurotransmitters, including dopamine, in the brain. Between the two types of MAO, MAO-B has been believed to be involved in dopamine degradation, which supports the idea that the therapeutic efficacy of MAO-B inhibitors in Parkinson’s disease can be attributed to an increase in extracellular dopamine concentration. However, this belief has been controversial. Here, by utilizing in vivo phasic and basal electrochemical monitoring of extracellular dopamine with fast-scan cyclic voltammetry and multiple-cyclic square wave voltammetry and ex vivo fluorescence imaging of dopamine with GRABDA2m, we demonstrate that MAO-A, but not MAO-B, mainly contributes to striatal dopamine degradation. In contrast, our whole-cell patch-clamp results demonstrated that MAO-B, but not MAO-A, was responsible for astrocytic GABA-mediated tonic inhibitory currents in the rat striatum. We conclude that, in contrast to the traditional belief, MAO-A and MAO-B have profoundly different roles: MAO-A regulates dopamine levels, whereas MAO-B controls tonic GABA levels.
- 9 July 2021
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 53 (7) , 1148-1158
Open AccessRedefining differential roles of MAO-A in dopamine degradation and MAO-B in tonic GABA synthesis
Monoamine oxidase (MAO) is believed to mediate the degradation of monoamine neurotransmitters, including dopamine, in the brain. Between the two types of MAO, MAO-B has been believed to be involved in dopamine degradation, which supports the idea that the therapeutic efficacy of MAO-B inhibitors in Parkinson’s disease can be attributed to an increase in extracellular dopamine concentration. However, this belief has been controversial. Here, by utilizing in vivo phasic and basal electrochemical monitoring of extracellular dopamine with fast-scan cyclic voltammetry and multiple-cyclic square wave voltammetry and ex vivo fluorescence imaging of dopamine with GRABDA2m, we demonstrate that MAO-A, but not MAO-B, mainly contributes to striatal dopamine degradation. In contrast, our whole-cell patch-clamp results demonstrated that MAO-B, but not MAO-A, was responsible for astrocytic GABA-mediated tonic inhibitory currents in the rat striatum. We conclude that, in contrast to the traditional belief, MAO-A and MAO-B have profoundly different roles: MAO-A regulates dopamine levels, whereas MAO-B controls tonic GABA levels.